image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 29.813
0.34 %
$ 958 M
Market Cap
24.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COLL stock under the worst case scenario is HIDDEN Compared to the current market price of 29.8 USD, Collegium Pharmaceutical, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COLL stock under the base case scenario is HIDDEN Compared to the current market price of 29.8 USD, Collegium Pharmaceutical, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one COLL stock under the best case scenario is HIDDEN Compared to the current market price of 29.8 USD, Collegium Pharmaceutical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart COLL

image
$34.0$34.0$33.0$33.0$32.0$32.0$31.0$31.0$30.0$30.0$29.0$29.0$28.0$28.0$27.0$27.0$26.0$26.0$25.0$25.0$24.0$24.015 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
631 M REVENUE
11.41%
170 M OPERATING INCOME
1.76%
69.2 M NET INCOME
43.68%
205 M OPERATING CASH FLOW
-25.39%
-288 M INVESTING CASH FLOW
-306.37%
-60.6 M FINANCING CASH FLOW
56.77%
178 M REVENUE
-2.30%
21.7 M OPERATING INCOME
-43.10%
2.42 M NET INCOME
-80.72%
55.4 M OPERATING CASH FLOW
-34.55%
-9.68 M INVESTING CASH FLOW
17.70%
-25.2 M FINANCING CASH FLOW
38.86%
Balance Sheet Collegium Pharmaceutical, Inc.
image
Current Assets 482 M
Cash & Short-Term Investments 163 M
Receivables 229 M
Other Current Assets 91 M
Non-Current Assets 1.18 B
Long-Term Investments 0
PP&E 20.2 M
Other Non-Current Assets 1.16 B
9.78 %13.74 %5.47 %69.80 %Total Assets$1.7b
Current Liabilities 510 M
Accounts Payable 3.93 M
Short-Term Debt 67.1 M
Other Current Liabilities 438 M
Non-Current Liabilities 925 M
Long-Term Debt 788 M
Other Non-Current Liabilities 137 M
4.68 %30.56 %54.92 %9.57 %Total Liabilities$1.4b
EFFICIENCY
Earnings Waterfall Collegium Pharmaceutical, Inc.
image
Revenue 631 M
Cost Of Revenue 254 M
Gross Profit 377 M
Operating Expenses 210 M
Operating Income 170 M
Other Expenses 101 M
Net Income 69.2 M
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00631m(254m)377m(210m)170m(101m)69mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
59.76% GROSS MARGIN
59.76%
26.91% OPERATING MARGIN
26.91%
10.96% NET MARGIN
10.96%
30.23% ROE
30.23%
4.16% ROA
4.16%
9.77% ROIC
9.77%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Collegium Pharmaceutical, Inc.
image
300m300m200m200m100m100m00(100m)(100m)(200m)(200m)(300m)(300m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 69.2 M
Depreciation & Amortization 169 M
Capital Expenditures -1.65 M
Stock-Based Compensation 32.4 M
Change in Working Capital -55 M
Others 16 M
Free Cash Flow 203 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Collegium Pharmaceutical, Inc.
image
Wall Street analysts predict an average 1-year price target for COLL of $42 , with forecasts ranging from a low of $36 to a high of $50 .
COLL Lowest Price Target Wall Street Target
36 USD 20.75%
COLL Average Price Target Wall Street Target
42 USD 40.88%
COLL Highest Price Target Wall Street Target
50 USD 67.71%
Price
Max Price Target
Min Price Target
Average Price Target
5050454540403535303025252020Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership Collegium Pharmaceutical, Inc.
image
Sold
0-3 MONTHS
853 K USD 2
3-6 MONTHS
4.94 M USD 3
6-9 MONTHS
0 USD 0
9-12 MONTHS
1.13 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: globenewswire.com - 1 month ago
Collegium Announces $25 Million Accelerated Share Repurchase Program STOUGHTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it has entered into an Accelerated Share Repurchase ("ASR") agreement with Jefferies LLC to repurchase $25 million of the Company's common stock. Collegium will execute the ASR as part of the $150 million share repurchase program authorized by its Board of Directors in January 2024. Upon completion of this ASR, Collegium will have $65 million remaining under the program. globenewswire.com - 1 month ago
Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript Call Start: 16:30 January 1, 0000 5:05 PM ET Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2025 Earnings Call May 8, 2025 16:30 ET Company Participants Ian Karp - Head, Investor Relations Vikram Karnani - President and Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants Les Sulewski - Truist Securities Serge Belanger - Needham & Co David Amsellem - Piper Sandler Operator Greetings and welcome to the Collegium Pharmaceutical First Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded. seekingalpha.com - 1 month ago
Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com - 1 month ago
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.43 per share. This compares to earnings of $1.45 per share a year ago. zacks.com - 1 month ago
Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress – Generated Q1'25 Quarterly Net Revenue of $177.8 Million, Up 23% Year-over-Year – – Grew Jornay PM ® Prescriptions by 24% Year-over-Year and Reported Quarterly Net Revenue of $28.5 Million; Jornay PM Prescribers Reached an All-Time-High – – Completed Jornay PM Field Force Expansion – – Generated Net Revenue of $149.2 Million from the Pain Portfolio, Up 3% Year-over-Year with All Three Core Products Recording Revenue Growth in the Quarter – – Ended Q1'25 with Cash, Cash Equivalents and Marketable Securities of $197.8 Million – – Board of Directors Authorized $25.0 Million Accelerated Share Repurchase Program – – Reaffirmed Full-Year 2025 Guidance – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass. globenewswire.com - 1 month ago
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 STOUGHTON, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report first quarter 2025 financial results after the market closes on Thursday, May 8, 2025. globenewswire.com - 1 month ago
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference STOUGHTON, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that management will participate in a fireside chat at the 24th Annual Needham Healthcare Conference being held virtually from April 7-10, 2025. globenewswire.com - 2 months ago
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting STOUGHTON, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present four posters highlighting real-world patient data from its differentiated pain portfolio at PainConnect 2025, the American Academy of Pain Medicine (AAPM)'s Annual Meeting, being held in Austin, TX, from April 3-6, 2025. globenewswire.com - 2 months ago
Collegium Announces Updates to its Board of Directors and Executive Leadership Team – Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman  and Gwen A. Melincoff, Board Member to Retire from Board – globenewswire.com - 3 months ago
8. Profile Summary

Collegium Pharmaceutical, Inc. COLL

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 958 M
Dividend Yield 0.00%
Description Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Contact 100 Technology Center Drive, Stoughton, MA, 02072 https://www.collegiumpharma.com
IPO Date May 7, 2015
Employees 357
Officers Mr. David Dieter Executive Vice President, General Counsel & Corporate Secretary Mr. Scott Sudduth Head of Technical Operations Ms. Colleen Tupper Executive Vice President & Chief Financial Officer Mr. Dean J. Patras Chief People Officer Mr. Scott Dreyer Executive Vice President & Chief Commercial Officer Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. Co-Founder & Chairman Ms. Jane Gonnerman Executive Vice President of Strategy & Corporate Development Mr. Vikram Karnani Chief Executive Officer, President, Executive Vice President & Director Dr. Thomas B. Smith FAAFP, M.D. Executive Vice President & Chief Medical Officer